An October 11th FiercePharma article covered a deal inked between Piramal and Johnson & Johnson in which the former paid $155 million up front for five generic pain drugs. In Paramal’s third healthcare buyout of 2016, it obtains all technical and marketing rights to the drugs, while J&J’s Janssen division will continue to manufacture them for a minimum of three years.
The deal gives Piramal firm footing in the generic injectable drug market, which is valued at $20 billion and relatively immune to the competition and pricing pressure that plagues the oral market. Four of the five drugs included in the deal are opioids, which face more hurdles for approval and therefore face fewer rivals. Should the drugs hit sales targets over the next 30 months, J&J will receive another $20 million in the deal.
